Literature DB >> 21844141

Mortality in patients with biopsy-proven giant cell arteritis: a south australian population-based study.

Jem Ninan1, Anh-Minh Nguyen, Antonia Cole, Maureen Rischmueller, Thomas Dodd, Peter Roberts-Thomson, Catherine L Hill.   

Abstract

OBJECTIVE: To compare mortality rates and cause of death in patients with biopsy-proven giant cell arteritis (GCA) with those in the general population.
METHODS: Patients with biopsy-proven GCA were identified from pathology reports of temporal artery biopsies in South Australia, from January 1, 1992, to December 31, 2006. All patients with biopsy-proven GCA were linked to the South Australian Births, Death and Marriage Registry to identify deaths until December 31, 2006. Standardized mortality ratios and relative survival (ratio of observed survival in GCA group to expected survival of general South Australian population, matched by age, sex, and calendar time) were calculated. The cause of death recorded on the death certificate was also documented.
RESULTS: There were 225 cases of biopsy-proven GCA (163 women and 62 men). The mean age at diagnosis of GCA was 78.2 years. The mean followup period was 66.2 months (SD 47.1 mo). During the followup period, there were 71 deaths in the GCA group (50 women, 21 men). The standardized mortality ratio was 0.99 (95% CI 0.77-1.25). The relative survival for different followup periods demonstrates that patients with GCA experienced similar mortality to the general population (age-matched and sex-matched). Death from cardiovascular causes (45%) was the most common, followed by infection (17%) and cancer (17%). Infection was a significantly more common cause of death in the first year (chi-squared, p = 0.0002).
CONCLUSION: Our population-based cohort study did not demonstrate any increased mortality risk for patients diagnosed with biopsy-proven GCA. The risk of death from infection early in the disease may be increased.

Entities:  

Mesh:

Year:  2011        PMID: 21844141     DOI: 10.3899/jrheum.101254

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  12 in total

Review 1.  Update on the management of giant cell arteritis.

Authors:  Janet Roberts; Alison Clifford
Journal:  Ther Adv Chronic Dis       Date:  2017-03-28       Impact factor: 5.091

2.  [Large vessel vasculitis].

Authors:  S Weigand; M Fleck
Journal:  Z Rheumatol       Date:  2014-06       Impact factor: 1.372

3.  Morphological features of temporal arteritis.

Authors:  William C Roberts; Saleha Zafar; Jo Mi Ko
Journal:  Proc (Bayl Univ Med Cent)       Date:  2013-04

4.  Concomitant association of giant cell arteritis and malignancy: a multicenter retrospective case-control study.

Authors:  S Deshayes; E Liozon; N Chanson; K Sacré; T Moulinet; C Blanchard-Delaunay; O Espitia; M Groh; M Versini; T Le Gallou; J-E Kahn; V Grobost; S Humbert; M Samson; R Mourot Cottet; K Mazodier; A Dartevel; J Campagne; A Dumont; B Bienvenu; M Lambert; A Daumas; D Saadoun; A Aouba; H de Boysson
Journal:  Clin Rheumatol       Date:  2019-01-07       Impact factor: 2.980

5.  Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis.

Authors:  Tanaz A Kermani; Kenneth J Warrington; Cynthia S Crowson; Steven R Ytterberg; Gene G Hunder; Sherine E Gabriel; Eric L Matteson
Journal:  Ann Rheum Dis       Date:  2012-12-19       Impact factor: 19.103

6.  Cryptococcal Meningitis in A Patient With Giant Cell Arteritis.

Authors:  Jin Lv; Qiankun Zhang
Journal:  Arch Rheumatol       Date:  2017-04-04       Impact factor: 1.472

Review 7.  The prediction and monitoring of toxicity associated with long-term systemic glucocorticoid therapy.

Authors:  Emma Harris; Ana Tiganescu; Sandy Tubeuf; Sarah Louise Mackie
Journal:  Curr Rheumatol Rep       Date:  2015-06       Impact factor: 4.592

8.  Vasculitis syndromes: Dealing with increased vascular risk and mortality in GCA.

Authors:  Sarah L Mackie; Bhaskar Dasgupta
Journal:  Nat Rev Rheumatol       Date:  2014-03-18       Impact factor: 20.543

9.  The prevalence of giant cell arteritis and polymyalgia rheumatica in a UK primary care population.

Authors:  Max Yates; Karly Graham; Richard Arthur Watts; Alexander James MacGregor
Journal:  BMC Musculoskelet Disord       Date:  2016-07-15       Impact factor: 2.362

10.  Incidence of giant cell arteritis in Western Norway 1972-2012: a retrospective cohort study.

Authors:  L K Brekke; A P Diamantopoulos; B-T Fevang; J Aβmus; E Esperø; C G Gjesdal
Journal:  Arthritis Res Ther       Date:  2017-12-15       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.